Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 1
Submit an article Journal homepage
1,803
Views
7
CrossRef citations to date
0
Altmetric
Oncology

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland

Christopher ParkerICON Health Economics & Epidemiology, Abingdon, UK; Correspondence[email protected]
,
Beth WoodsCentre for Health Economics, University of York, York, UK;
,
James EatonICON Health Economics & Epidemiology, Abingdon, UK;
,
Esprit MaCenter for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA;
,
Ross SelbyTakeda UK Ltd, Buckinghamshire, UK;
,
Eugene BensonTakeda UK Ltd, Buckinghamshire, UK;
,
Andreas EngstromTakeda Pharma AB, Stockholm, Sweden;
,
Peter SajosiMillennium Pharmaceuticals Inc., Cambridge, MA, USA,a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;
,
Andrew BriggsICON Health Economics & Epidemiology, Abingdon, UK; ;Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK
&
Vijayveer BonthapallyMillennium Pharmaceuticals Inc., Cambridge, MA, USA,a wholly owned subsidiary of Takeda Pharmaceutical Company Limited;
show all
Pages 8-18 | Received 03 May 2016, Accepted 19 Jul 2016, Published online: 11 Aug 2016

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Monika Raut, Gautamjeet Singh, Immaculata Hiscock, Sheetal Sharma & Nameeta Pilkhwal. (2022) A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma. Expert Review of Hematology 15:7, pages 607-617.
Read now
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now

Articles from other publishers (5)

Jalal Arabloo, Samad Azari, Hasan Abolghasem Gorji, Aziz Rezapour, Vahid Alipour & ‬Seyed Jafar Ehsanzadeh. (2023) Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review. European Journal of Clinical Pharmacology 79:11, pages 1443-1452.
Crossref
T.I. Ionova, A.A. Amdiev, M.I. Andrievskikh, E.A. Baryakh, E.V. Vasil’ev, M.V. Volkov, E.M. Volodicheva, V.V. Ivanov, O.V. Kaverina, K.D. Kaplanov, T.Yu. Klitochenko, V.I. Kurakin, D.G. Lazareva, O.G. Larionova, K.V. Lepik, I.B. Lysenko, V.Ya. Melnichenko, R.I. Minullina, O.V. Mironov, E.N. Misyurina, N.B. Mikhailova, N.E. Mochkin, Tatyana Pavlovna Nikitina, T.S. Petrova, N.M. Porfirieva, O.A. Rukavitsyn, A.A. Samoilova, R.N. Safin, P.I. Simashova, E.G. Smirnova, N.A. Trenina, N.V. Fadeeva, G.N. Khusainova, V.L. Chang, T.V. Shelekhova & D.G. Sherstnev. (2022) The Efficacy of Brentuximab Vedotin in Relapsed/Refractory Classical Hodgkin’s Lymphoma and Quality of Life: Results of a Multi-Center Observational Prospective Study in the Context of Real Clinical Practice. Clinical oncohematology 15:1, pages 42-53.
Crossref
Anu Korula, Anup Joseph Devasia, Uday Kulkarni, Fouzia N. Abubacker, Kavitha M. Lakshmi, Aby Abraham, Alok Srivastava, Biju George & Vikram Mathews. (2019) Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. British Journal of Haematology 188:6, pages 930-934.
Crossref
Panayotis Kaloyannidis, Mark Hertzberg, Kate Webb, Athanasios Zomas, Rudolf Schrover, Michael Hurst, Ian Jacob, Thalia Nikoglou & Joseph M. Connors. (2019) Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. British Journal of Haematology 188:4, pages 540-549.
Crossref
Saad Akhtar. (2017) High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm. Hematology/Oncology and Stem Cell Therapy 10:4, pages 272-276.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.